The U.S. Food and Drug Administration (FDA) updated the indication and usage information on the label for dapagliflozin, effective 2026-04-08. This revision specifies that dapagliflozin tablets are now indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus who also have either established cardiovascular disease or multiple cardiovascular risk factors.
Background
Dapagliflozin is a medication whose label has been updated by the FDA to include a new specific indication. The revised indication focuses on its role in cardiovascular risk management for a particular patient population, expanding its recognized therapeutic scope.
What this means
This label update clarifies and expands the approved use of dapagliflozin for a specific patient population. For adults living with type 2 diabetes mellitus, particularly those who also present with established cardiovascular disease or possess multiple cardiovascular risk factors, dapagliflozin is now explicitly indicated to help reduce their risk of hospitalization due to heart failure. This provides healthcare providers with a clear, FDA-approved guideline for leveraging dapagliflozin in managing cardiovascular outcomes within this vulnerable group, reinforcing its role beyond glycemic control. The update underscores the drug's recognized benefit in mitigating a significant cardiovascular complication. This new indication is a crucial development for clinicians aiming to optimize treatment strategies for patients at risk of heart failure hospitalization, offering a targeted approach to improve patient outcomes.
Source
The information regarding this label revision was obtained from the U.S. Food and Drug Administration (FDA) and is publicly available through the DailyMed database. The updated indication and usage details for dapagliflozin became effective on 2026-04-08, and the full label can be verified on dailymed.nlm.nih.gov.